DrugPatentWatch Database Preview

Details for Patent: 8,329,216

« Back to Dashboard

Which drugs does patent 8,329,216 protect, and when does it expire?

Patent 8,329,216 protects OPANA ER and is included in one NDA.

This patent has forty-seven patent family members in sixteen countries.

Summary for Patent: 8,329,216

Title:	Oxymorphone controlled release formulations
Abstract:	The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.
Inventor(s):	Kao; Haui-Hung (Syosset, NY), Baichwal; Anand R. (Wappingers Falls, NY), McCall; Troy (Smyrna, GA), Lee; David (Chadds, PA)
Assignee:	Endo Pharmaceuticals Inc. (Chadds Ford, PA)
Application Number:	11/427,438
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Use; Composition; Delivery;

Drugs Protected by US Patent 8,329,216

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-001	Dec 9, 2011		DISCN	Yes	No			Y
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-002	Dec 9, 2011		DISCN	Yes	No			Y
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-003	Dec 9, 2011		DISCN	Yes	No			Y
Endo Pharms	OPANA ER	oxymorphone hydrochloride	TABLET, EXTENDED RELEASE;ORAL	201655-004	Dec 9, 2011		DISCN	Yes	No			Y

Non-Orange Book US Patents Family Members for Patent 8,329,216

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,820,982	Oxymorphone controlled release formulations
7,276,250	Sustained release formulations of oxymorphone
8,309,122	Oxymorphone controlled release formulations

International Patents Family Members for US Patent 8,329,216

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Poland	208484
Poland	367277
Poland	207748
Poland	366430